Latest findings on neflamapimod to be featured in presentations demonstrating its impact on dementia with Lewy bodies (DLB) disease progression, biomarkers of neurodegeneration, and basal forebrain atrophy, as well as optimal dosing strategies
CervoMed's science to be featured in five presentations at AAIC
BOSTON, July 06, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that the upcoming AAIC meeting will feature five presentations highlighting the company's clinical science, including four on neflamapimod, its oral, small molecule, drug candidate targeting critical disease processes underlying degenerative disorders of the brain. The AAIC meeting will take place in London from July 12-15, 2026.
DLB is the second most common progressive dementia after Alzheimer's disease (AD), affecting millions worldwide. Patients may experience a combination of decline in cognitive function, cognitive fluctuations, visual hallucinations, and sleep disorders, as well as motor symptoms similar to Parkinson's disease. There are no approved treatments for DLB in the United States or European Union, and the current standard-of-care therapies only temporarily relieve symptoms.
Scientific Presentations
Topic: The Oral p38α Kinase Inhibitor Neflamapimod Slows the Rate of Clinical Worsening in Dementia with Lewy Bodies (DLB)
Poster Session: Drug Development: Human
Date/Time: Sunday, July 12, 7:30 AM - 4:15 PM BST
This presentation shares exploratory analyses from the Phase 2 study of neflamapimod in DLB, looking at the clinical impact of treatment in patients with low plasma p-tau181, and higher plasma drug concentrations.
Topic: The Effect of Treatment with Neflamapimod on Basal Forebrain Atrophy as Assessed by MRI in DLB
Poster Session: Developing Topics: Drug Development
Date/Time: Monday, July 13, 7:30 AM - 4:15 PM BST
This poster shares data relating to the impact of neflamapimod on the progression of basal forebrain atrophy as determined by structural and functional MRI results from the RewinD-LB Phase 2 clinical trial. Basal forebrain atrophy has emerged as a key biomarker of disease progression in DLB.
Topic: The Plasma Drug Exposure-Response Relationship of Neflamapimod in the Rewind-LB Trial in DLB patients
Poster Session: Developing Topics: Drug Development
Date/Time: Monday, July 13, 7:30 AM - 4:15 PM BST
This presentation will feature data on the in vitro concentration-response relationship for neflamapimod's primary pharmacologic effect— inhibition of interleukin (IL)-1β signaling—and the pharmacokinetic-pharmacodynamic (PK-PD) relationships, with a focus on RewinD-LB.